In the nematode C. elegans, immobility induced by the anesthetic halothane is coupled to its ability to modulate neuronal resting membrane potential, perhaps through effects on leak channels; a similar anesthetic, isoflurane, appears to work a different way.
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Anesthetic drugs have been considered one of the most important medical advances of all time, and are used in about 240 million surgical cases every year across the world [1] . Although anesthetics have now reached the stage of being standard-of-care, are apparently safe and are essentially taken-for-granted, we do not yet know how or why the drugs produce the state of anesthesia, a term coined by Oliver Wendell Holmes in 1846. Early theories focused on the lipid bilayer as the primary target, buoyed by the strong correlation between hydrophobicity and anesthetic potency (the Overton-Meyer relationship). However, a host of inconsistencies shifted investigators' attentions to other macromolecular targets. The finding that inhibition of the activity of a lipid-free enzyme, firefly luciferase, could mimic the Overton-Meyer relationship put proteins squarely in the spotlight [2] , and lipid-based ideas have subsequently dwindled (perhaps prematurely). Of course, the proteome is large, and the very fact that a firefly enzyme of little human or neuronal relevance can satisfy the Overton-Meyer relationship so well suggests that finding the truly important targets might be akin to the proverbial needle in the haystack.
But progress has been made. A wide variety of ion channels and neurotransmitter receptors have been implicated to various degrees [3] , but none has emerged as being both necessary and sufficient [4] . Combining this with the knowledge that all organisms can be anesthetized within a fairly narrow range of anesthetic concentrations, the fact that resistance is uncommon, and that antagonists do not exist, leads one to suspect that the anesthetic target is more process than protein, or that the critical protein is exceptionally well-conserved. Given that an exceptionally conserved target underlying anesthesia is likely to have been identified by now, we seem stuck with the idea that a process consisting of several, or even many, proteins underlies anesthetic action. The paper in this issue of Current Biology by Singaram et al. [5] challenges this idea.
Singaram et al. [5] took advantage of recent developments in optogenetics [6] to test the hypothesis that modulation of the resting membrane potential controls the anesthetic state. The idea is that resting membrane potential is lowered via effects, direct or indirect, of these small drugs on specific ion channels, making typical depolarizing events less effective in propagating signals. The authors used the tiny transparent nematode Caenorhabditis elegans as a model, having previously established its validity for anesthetic mechanism research [7] . These small metazoans constantly move in search of food, and respond to touch or light by altering their course and speed. Thus, their mobility, either spontaneous or elicited, serves as a useful and robust anesthetic endpoint -much the same as it does in humans. The authors have shown that the wild-type nematode responds to a wide range of anesthetics in an Overton-Meyer manner at concentrations within an order of magnitude of those producing the same endpoint in mammals [8] .
Singaram et al.
[5] generated worms expressing channelrhodopsin-2, an ion channel causing depolarization when activated by light, in cholinergic neurons, and found that they could optically reverse the immobilizing effect of the volatile anesthetic halothane (Figure 1) . Activation of halorhodopsin expressed in the same neurons, a channel that produces hyperpolarization, dramatically increased the sensitivity of the nematode to halothane. These manipulations of the resting membrane potential alter halothane sensitivity by about 25-fold, an unprecedented magnitude given that the population variance, as reflected by Hill coefficients of 20 or more, is exceedingly small. For example, prior genetic or pharmacological manipulations rarely produced mobility effects exceeding two-fold.
Finally, Singaram et al.
[5] went a step further to implicate the resting membrane potential by introducing either loss-of-function or gain-of-function mutations into ion channels known to modulate the resting membrane potential. In each case, the predicted result was obtained. It is important to point out, however, that this does not necessarily implicate these ion channels as direct targets for halothane. There are a host of possible targets that can have effects on the resting membrane potential, and it has been estimated that halothane can interact specifically with as much as 15% of the proteome [9] . So far, this all seems consistent with the notion that the anesthetic target is a process, the resting membrane potential.
But this also leads to the obvious criticism that the resting membrane potential itself may not be the modulated process, but rather an orthogonal or opposed process. Singaram et al. [5] anticipated this by examining another anesthetic, isoflurane (physicochemically very similar to halothane). Remarkably, they found that isoflurane sensitivity is unaltered by the same treatments. This same group has long suggested that targets might be different for even these small, promiscuous volatile anesthetics [10] , but this is a startling confirmation that targets could be fundamentally different; one or more targets can actually distinguish halothane from isoflurane, moving us away from the process-as-target idea. Ion channels with this degree of selectivity have not yet emerged, and the only high resolution complexes in the Protein Database (http://www.rcsb. org/pdb) show that isoflurane and halothane occupy the same protein binding sites with comparable, and relatively high, affinity [11] .
What targets then? One possibility might be within the large family of G-protein-coupled receptors. The largest subgroup of these receptors, those underlying olfaction, have evolved to detect and distinguish small volatile molecules from each other, and any anesthesiologist knows that halothane and isoflurane smell different! In fact, previous work has shown that individual olfactory receptors can distinguish halothane from isoflurane from sevoflurane [12] . Finally, these receptors are not just expressed in the nose -some are found in the brain and spinal cord -suggesting that they might serve an internal chemical sensing role, in addition to their more familiar external role. Finding such a target should be of high priority, as this sort of selectivity argues strongly that necessary and sufficient targets might exist and, more importantly, that further anesthetic drug optimization can occur.
As an aside, this paper [5] should be of general interest to experimental biologists. Anesthetic drugs are clearly not non-specific enough to be ignored in experimental models. Their required (and justified) use in animals to minimize pain and suffering may contaminate data in unpredictable ways. But, because this study suggests not all anesthetics act alike, additional controls with other anesthetics should allow a greater degree of confidence in results.
